Imbruvica Effective Against Relapsed or Refractory Mantle Cell Lymphoma

According to an open-label multicenter, phase 2 study coming from the US and Europe, the oral Bruton tyrosine kinase inhibitor Ibrutinib (Imbruvica) is effective in treating patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Michael Wang, MD, of the University of Texas MD Anderson Cancer Center, and colleagues recruited a total of 111 patients with R/R MCL and treated them with oral ibrutinib daily for a median of 8.3 months.

The overall response rate (ORR) was 67%, while 23 percent of patients achieved a complete response. The overall survival rate at 24 months was 47 percent, a figure that reflects the challenges of treating this disease and the need to appreciate small victories.

"MCL is not curable and relapse is common with the majority of patients dying from progressive disease (PD)," Wang and colleagues wrote. "In addition, the commonly used chemotherapeutic regimens can cause myelosuppression that can make treatment particularly difficult in elderly patients [so] novel agents with improved efficacy and less toxicity are needed."

The most commonly experienced adverse events included diarrhea, fatigue, and nausea

The team reported its findings in the journal Blood.

Sources: Blood, MedPage Today

More Articles

More Articles

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

Diagnosing lymphoma is one of the more difficult diagnoses to make in cancer medicine, and contrary to perception, diagnosing lymphoma is not made...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Follicular lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

Lymphoma is not difficult to diagnose once a patient and doctor begin to look for signs of cancer. However, Lymphoma–especially...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...